Protect Your Bank Account Before It’s Too Late

For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …

Stop right now and do these 3 things to protect yourself

Andrea Sabens Biography and Net Worth

CAO of Lantheus

Ms. Andrea Sabens is a Chief Accounting Officer at Lantheus Holdings, Inc. She received her undergraduate degree from the University of New Hampshire, a graduate degree from Southern New Hampshire University and an MBA from Southern New Hampshire University.

What is Andrea Sabens' net worth?: The estimated net worth of Andrea Sabens is at least $4.15 million as of April 15th, 2024. Ms. Sabens owns 63,239 shares of Lantheus stock worth more than $4,145,949 as of April 26th. This net worth evaluation does not reflect any other investments that Ms. Sabens may own. Learn More about Andrea Sabens' net worth.
How old is Andrea Sabens?: Ms. Sabens is currently 45 years old. There are 6 older executives and no younger executives at Lantheus. The oldest executive at Lantheus is Mr. Brian A. Markison, CEO & Director, who is 65 years old. Learn More on Andrea Sabens' age.
How do I contact Andrea Sabens?: The corporate mailing address for Ms. Sabens and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected]. Learn More on Andrea Sabens' contact information.
Has Andrea Sabens been buying or selling shares of Lantheus?: Within the last three months, Andrea Sabens has sold $20,882.84 of Lantheus stock. Most recently, Andrea Sabens sold 341 shares of the business's stock in a transaction on Monday, April 15th. The shares were sold at an average price of $61.24, for a transaction totalling $20,882.84. Following the completion of the sale, the chief accounting officer now directly owns 63,239 shares of the company's stock, valued at $3,872,756.36. Learn More on Andrea Sabens' trading history.
Who are Lantheus' active insiders?: Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.
Are insiders buying or selling shares of Lantheus?: During the last year, Lantheus insiders bought shares 1 times. They purchased a total of 60,431,039 shares worth more than $57,409,487.05. During the last year, insiders at the medical equipment provider sold shares 19 times. They sold a total of 148,672 shares worth more than $10,389,459.87. The most recent insider tranaction occured on April, 15th when CAO Andrea Sabens sold 341 shares worth more than $20,882.84. Insiders at Lantheus own 1.5% of the company. Learn More about insider trades at Lantheus.
Information on this page was last updated on 4/15/2024.

Andrea Sabens Insider Trading History at Lantheus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/15/2024	Sell	341	$61.24	$20,882.84	63,239
2/13/2024	Sell	341	$55.31	$18,860.71	58,403
1/16/2024	Sell	341	$56.01	$19,099.41	58,744
11/13/2023	Sell	341	$63.57	$21,677.37	59,426
7/19/2023	Sell	1,752	$90.87	$159,204.24	59,767
5/15/2023	Sell	385	$99.36	$38,253.60	61,519
4/17/2023	Sell	386	$88.67	$34,226.62	61,904
3/15/2023	Sell	386	$71.58	$27,629.88	62,290
3/6/2023	Sell	7,705	$72.56	$559,074.80	63,626
1/17/2023	Sell	386	$52.97	$20,446.42	60,846
12/15/2022	Sell	386	$53.75	$20,747.50	61,232
10/17/2022	Sell	386	$70.50	$27,213.00	62,004
9/15/2022	Sell	386	$85.83	$33,130.38	62,390
8/15/2022	Sell	386	$82.82	$31,968.52	62,776
7/18/2022	Sell	1,093	$71.47	$78,116.71	63,162
7/15/2022	Sell	386	$69.12	$26,680.32	64,255
6/15/2022	Sell	386	$62.87	$24,267.82	64,441
3/1/2022	Sell	2,409	$48.04	$115,728.36
1/18/2022	Sell	1,242	$26.93	$33,447.06
12/15/2021	Sell	1,242	$26.72	$33,186.24
11/15/2021	Sell	1,242	$30.47	$37,843.74
10/15/2021	Sell	1,242	$23.71	$29,447.82
8/16/2021	Sell	1,242	$25.46	$31,621.32	67,312

Andrea Sabens Buying and Selling Activity at Lantheus

Lantheus Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Today's Range

Now: $65.56

$65.09

$66.26

50 Day Range

MA: $61.46

$56.52

$68.26

2 Week Range

Now: $65.56

$50.20

$100.85

Volume

584,575 shs

Average Volume

1,030,900 shs

Market Capitalization

$4.49 billion

P/E Ratio

14.13

Dividend Yield

N/A

Beta

0.53

Protect Your Bank Account Before It’s Too Late

From Weiss Ratings | Ad